Leading Anti-Cancer Drugs and Associated Market 2012-2022 - new market research report - Transworld News

Leading Anti-Cancer Drugs and Associated Market 2012-2022 - Glivec/Gleevec (Novartis): Glivec, known as Gleevec in the US, is a protein kinase inhibitor developed by Novartis. In 2001, Glivec was granted fast-track approval for treating chronic myeloid ...

AB SCIENCE : Recruitment of the First Patient for the Phase 3 Study on Gleevec®-Resistant GIST, Comparing Masitinib with Sunitinib - 4-traders (press release)

AB Science SA (Euronext Paris - FR0010557264 - AB)(Paris:AB), a pharmaceutical company specialized in research, development and commercialization of protein kinase inhibitors (PKI), announces today the recruitment of the first patient in a phase 3 study ...

Stroke: Imatinib may reduce the risk of tPA-associated bleeding - Xagena Medical News

Imatinib (Gleevec / Glivec ). The results have demonstrated that Imatinib greatly reduces the risk of tPA-associated bleeding in mice, even when tPA was given as late as five hours after the stroke had begun. The LICR team, in collaboration with the ...

Fidelity Biosciences invests in Blueprint Medicines - Boston Globe

A Globe story then noted that Blueprint Medicine’s scientific cofounders, Dr. Nicholas Lydon and Dr. Brian Druker, had won the prestigious Lasker-DeBakey Clinical Medical Research Award in 2009 for their role in developing Gleevec, a kinase ...

Pledges to drugs discovery centre take investment to £50m level - scotsman.com

Kinase research accounts for more than 50 per cent of spending on global cancer drug discovery. The drug Gleevec, which has transformed a previously fatal form of leukaemia into a manageable disease, is one example of a kinase-targeting drug that has been ...

An ASCO Bio-Pharma Catalyst Trade With A Promising Leukemia Drug - Seekingalpha.com

Novartis (NVS) Drugs: Gleevec and Tasigna. The launch of Gleevec (imatinib) for the treatment of chronic myeloid leukemia in 2003 catapulted Novartis into a major oncology player and made the company into a poster child for oncologic success: an expensive ...

Grant to fund use of kinase test in HER2-positive breast cancer - Bladen Journal

Tremendous efforts have been made to develop kinase inhibitors as cancer treatments, which have resulted in key drugs such as Herceptin®, Tykerb®, and Gleevec®. However, in spite of the effectiveness of this class of cancer drugs, most cancers ...

Dundee University disease research to receive £14m investment - Courier

The drug Gleevec, which has transformed a previously fatal form of leukaemia into a manageable disease, is one example of a kinase-targeting drug which has been introduced to the market in recent years. Speaking for the pharmaceutical companies in the ...

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - PharmiWeb

Gleevec®* (imatinib mesylate) in the treatment of patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic-phase. Long-term follow up data (6 years) from the Phase 3 study (-034) that evaluated the ...